Xenetic Biosciences, Inc. (XBIO)

Market Cap	6.15M
Revenue (ttm)	2.54M
Net Income (ttm)	-4.13M
Shares Out	1.54M
EPS (ttm)	-2.71
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	345
Open	3.990
Previous Close	3.770
Day's Range	3.750 - 3.975
52-Week Range	2.550 - 5.970
Beta	2.67
Analysts	Hold
Price Target	n/a
Earnings Date	May 9, 2024

About XBIO

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies for hard to treat cancers. The company's proprietary DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments that targets pancreatic cancer comprising pancreatic ductal adenocarcinoma, colorectal carcinoma, and other gastrointestinal cancer. Its product pipeline in...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Jeffrey F. Eisenberg Esq.
• Employees: 4
• Stock Exchange: NASDAQ
• Ticker Symbol: XBIO

Financial Performance

In 2023, XBIO's revenue was $2.54 million, an increase of 48.80% compared to the previous year's $1.71 million. Losses were -$4.13 million, -36.90% less than in 2022.